Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|HER2-Positive Breast Carcinoma|Metastatic Breast Carcinoma
Interventions: DRUG: Copanlisib|BIOLOGICAL: Pertuzumab|BIOLOGICAL: Trastuzumab
Sponsor: National Cancer Institute (NCI)